Mirion Q1: Orders Surge but EBITDA In Line, No Guidance Change

What happened

Mirion reported Q1 2026 results highlighting substantial orders growth driven by nuclear power demand, while Adjusted EBITDA came in as expected and margins held. The company's RPO stood at $1.104B at year-end 2025, with ~49% expected to convert in 2026, and management reaffirmed FY2026 guidance for adjusted EBITDA of $285-300M and adjusted FCF of $155-175M. Despite the orders momentum, the stock trades at 28.5x EV/EBITDA with net debt/EBITDA of 4.0x, leaving no room for execution slip. The key question remains whether the large opportunity pipeline continues to convert into disclosed awards, as the 2025 pipeline contribution of ~$150M needs to be replicated. For now, the Q1 report buys time but does not de-risk the leverage or valuation story.

Implication

Mirion's Q1 orders growth supports the nuclear narrative, but the as-expected EBITDA and lack of guidance upgrade mean the stock is fairly priced at current levels. The 28.5x EV/EBITDA multiple already embeds success, so investors should require either a lower entry near $19 or evidence of accelerating RPO growth beyond $1.1B before increasing exposure. Monitor Q2 for RPO trajectory and any large-order disclosures; a miss on either could catalyze a re-rating lower given elevated leverage.

Thesis delta

The Q1 results provide partial validation of the nuclear demand thesis but no incremental catalyst. The thesis shifts from 'waiting for orders evidence' to 'needing orders evidence to sustain multiple.' RPO stability and guidance reaffirmation are now table stakes; the next 3-6 months require RPO growth above $1.15B or organic growth guidance above 7% to drive upside.